Viva Biotech Holdings has announced significant advancements in the field of cyclic peptide therapeutics, emphasizing their potential to bridge the gap between small molecules and large biologics. The company's integrated platform for peptide drug discovery and development, which spans from hit discovery to preclinical candidates, has delivered over 82,000 protein structures and synthesized more than 3,000 peptides, with a focus on cyclic peptides. These advancements have already been presented, highlighting the use of AI-enabled peptide design, DEL screening, and phage display in the discovery process. With an emphasis on cyclic peptides' ability to target traditionally "undruggable" protein-protein interactions, Viva Biotech aims to continue collaborating with global partners to translate these innovations into real-world therapeutics.